1,2:5,6-di-O-isopropylidene-3-(2-hydroxyethyl)-α-D-allofuranoside | 18427-19-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,2:5,6-di-O-isopropylidene-3-(2-hydroxyethyl)-α-D-allofuranoside
• 英文别名: 2-[(3aR,5S,6R,6aR)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-yl]ethanol
• CAS: 18427-19-5
• 化学式: C₁₄H₂₄O₆
• 分子量: 288.341
• InChiKey: PDCHSCKYQZTHOQ-RMPHRYRLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  66.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1,2:5,6-di-O-isopropylidene-3-(2-hydroxyethyl)-α-D-allofuranoside 在 咪唑 、 碘 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以94%的产率得到3-deoxy-3-(2-iodoethyl)-1,2:5,6-bis-O-(1-methylidene)-α-D-allofuranose
  参考文献：
  名称：

  对Bielschowskysin的14元环状亚基的Cis选择性RCM研究

  摘要：

  使用天然手性起始原料详细描述了一个简单的（Z）选择环闭合复分解（RCM）路线，该路线通向Bielschowskysin的14元碳环。非生产性的RCM底物归因于钌催化剂的炔烃螯合，以及在mb状前体中的空间位阻，这最终通过使用涉及C8-季甲醇中心的环状二醇亚苄基保护而得以解决。

  DOI：

  10.1021/acs.joc.0c02984
• 作为产物：
  描述：

  3-deoxy-3-C-<(ethoxycarbonyl)methyl>-1,2:5,6-di-O-isopropylidene-α-D-allofuranose 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 1,2:5,6-di-O-isopropylidene-3-(2-hydroxyethyl)-α-D-allofuranoside
  参考文献：
  名称：

  Highly stereoselective total synthesis of tylonolide, the aglycon of the 16-membered macrolide antibiotic tylosin. I. Construction of the C-1-C-8 chiral centers.

  摘要：

  为了合成 16 元大环内酯抗生素泰洛新的苷元--泰洛内酯，以 D-葡萄糖为原料合成了与 C-1-C-9 段相对应的 Prelog-Djerassi 内酯型化合物 (4)。该化合物成功地采用了苄基、4-甲氧基苄基和 3，4-二甲氧基苄基等苄基型羟基保护基团，以及一些环状和非环状立体控制反应，如氢硼化反应、催化氢化反应和格氏反应。

  DOI：

  10.1248/cpb.35.2209

文献信息

• MONOSACCHARIDE DERIVATIVES
  申请人：Sattigeri Jitendra Viswajanani

  公开号：US20080114031A1

  公开（公告）日：2008-05-15

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及单糖衍生物作为抗炎剂。本发明的化合物可用于抑制和预防炎症及相关病理，包括炎症和自身免疫疾病，如支气管哮喘、类风湿性关节炎、I型糖尿病、多发性硬化症、异体移植排斥、银屑病、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒和过敏性鼻炎。还提供了包含本发明披露的化合物的药物组合物，以及使用这些化合物治疗支气管哮喘、慢性阻塞性肺病、类风湿性关节炎、多发性硬化症、I型糖尿病、银屑病、异体移植排斥、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒、过敏性鼻炎以及其他炎症性和/或自身免疫障碍的方法。
• Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents
  申请人：Sattigeri Vishwajanani Jitendra

  公开号：US20090048186A1

  公开（公告）日：2009-02-19

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及单糖衍生物作为抗炎剂。本发明的化合物可用于抑制和预防炎症及相关病理，包括炎症和自身免疫疾病，如支气管哮喘、类风湿性关节炎、I型糖尿病、多发性硬化症、异体移植排斥、银屑病、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒和过敏性鼻炎。还提供了含有本发明披露的化合物的药物组合物，以及使用这些化合物治疗支气管哮喘、慢性阻塞性肺病、类风湿性关节炎、多发性硬化症、I型糖尿病、银屑病、异体移植排斥、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒、过敏性鼻炎以及其他炎症性和/或自身免疫障碍的方法。
• MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS
  申请人：Ranbaxy Laboratories Limited

  公开号：EP1842855A3

  公开（公告）日：2007-12-05

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, psoriasis, allograft rejection, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及单糖衍生物作为抗炎药物。本文中所述的化合物可用于抑制和预防炎症及相关病理，包括支气管哮喘、类风湿关节炎、1型糖尿病、多发性硬化症、移植排斥、牛皮癣、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒和过敏性鼻炎等炎症和自身免疫性疾病。还提供了含有本文披露的化合物的药理组合物以及治疗支气管哮喘、慢性阻塞性肺病、类风湿关节炎、多发性硬化症、1型糖尿病、牛皮癣、移植排斥、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒、过敏性鼻炎和其他炎症和/或自身免疫性疾病的方法。
• Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
  申请人：Seth Punit P.

  公开号：US09290534B2

  公开（公告）日：2016-03-22

  The present disclosure describes oligomeric compounds having at least one bicyclic nucleoside attached to the 3′ or 5′ termini by a neutral internucleoside linkage and methods of using the oligomeric compounds. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

  本公开描述了具有至少一个双环核苷酸连接到3′或5′末端的寡聚化合物，其通过中性核苷酸间连接，并描述了使用这些寡聚化合物的方法。在某些实施例中，本文提供的寡聚化合物与靶RNA的部分杂交，导致靶RNA的正常功能丧失。
• Highly stereoselective total synthesis of tylonolide, the aglycon of the 16-membered macrolide antibiotic tylosin. I. Construction of the C-1-C-8 chiral centers.
  作者：TATSUYOSHI TANAKA、YUJI OIKAWA、TATSUO HAMADA、OSAMU YONEMITSU

  DOI：10.1248/cpb.35.2209

  日期：——

  In order to synthesize tylonolide, the aglycon of the 16-membered macrolide antibiotic tylosin, a Prelog-Djerassi lactone-type compound (4) corresponding to the C-1-C-9 segment was synthesized from D-glucose. Benzyl-type protecting groups for hydroxy functions, such as benzyl, 4-methoxybenzyl, and 3, 4-dimethoxybenzyl groups, as well as some cyclic and acyclic stereocontrolled reactions, such as hydroboration, catalytic hydrogenation, and Grignard reaction, were successfully employed.

  为了合成 16 元大环内酯抗生素泰洛新的苷元--泰洛内酯，以 D-葡萄糖为原料合成了与 C-1-C-9 段相对应的 Prelog-Djerassi 内酯型化合物 (4)。该化合物成功地采用了苄基、4-甲氧基苄基和 3，4-二甲氧基苄基等苄基型羟基保护基团，以及一些环状和非环状立体控制反应，如氢硼化反应、催化氢化反应和格氏反应。